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Bacillus and Pseudomonas Genera as a Potential Source for
Novel Antibiotics
Cory Jayne and Dr. Lori Scott, Augustana College

INTRODUCTION

METHODS

The need for new antibiotics is an ever-growing issue in the
medical field due to a multitude of issues, most notably the
over-prescription of antibiotics and the non-cooperation of
patients in following the advised prescription time period.1 This
has led to multiple drugs becoming resistant to the various
drugs used to treat them. The ESKAPE bacteria are a group of
six bacteria that are considered in critical or high need of
finding new antibiotics (Figure 1). The six bacteria are
Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, and Enterobacter spp. Through collaboration with
the Tiny Earth Project Initiative, a worldwide database focused
on finding novel antibiotics for the treatment of the ESKAPE
strains, we hope to discover antibiotics through bacteria found
in soil.2

In collaboration with the Tiny Earth Project Initiative we were
able to use many of their procedures described.2 Unless otherwise
noted, all of the procedures were followed exactly.
•
•
•
•
•
•
•

•
•
•

Collect soil sample
Serial Dilution of soil samples and isolation of microbes
Media and selective media for isolation (10% TSA, LB, PDA)
Formation of master plates
Testing microbial isolates for the production of secondary
metabolites with antibiotics (Staphylococcus epidermidis,
Bacillus subtilis, and Erwinia carotovora)
Formation of streak plates to allow for further testing
Differential media for potential identification of isolates
(MacConkey, Simmons’ citrate, MSA, TSI slants, and blood
agar)
PCR of any antibiotic producing microbes (16S rRNA gene
primers are 27F and 1492R)
Gel electrophoresis of PCR products (1% agarose gel)
Sequencing of the DNA of 16S rRNA gene (Iowa Institute of
Human Genetics, University of Iowa)

RESULTS

RESULTS (CONTINUED)

Figure 4. 16S rRNA gene sequence data, showing that isolate
CJ-1-TSA, and CJ-4-PDA are from the genus Pseudomonas
and Bacillus respectively.6 The description section lists the
possible strains that our unknown isolates were. Query cover is
the percentage of the actual gene that our sequenced data matches
up with, in this case we did not amplify the entire gene, but
instead about 98%. The E value is the likelihood that we just
randomly obtained these strains. Finally, the percent identity is
the percent of nucleotides from our isolates that line up exactly
with the known strains in the description.

Fig 1. The ESKAPE strains are becoming more resistant to
the antibiotics used to treat them.5 The graph shows common
antibiotics and what percentage of just one strain, Enterococcus
faecium, is resistant to them.

With the rise of methicillin-resistant Staphylococcus aureus
(MRSA), among various other bacteria, hospital-acquired
infections (HAI) are becoming a more significant issue.1
Staphylococcus aureus and different other strains of the
Staphylococcus genus are commonly found in surgical site
infections (SSI).3 A study done by Pal et al. showed that 20.8%
of patients in a rural hospital in India obtained either a primary
or secondary SSI after their procedure. A primary SSI is an
infection typically occurring within seven days of the
operation, generally while still in the hospital. A secondary SSI
is an infection acquired after leaving the hospital. Of the
patients who acquired an SSI post-surgery, 64.8% had the
bacteria Staphylococcus in the infection 69.9% of which was
MRSA, or methicillin-sensitive Staphylococcus aureus
(MSSA). The discovery of new antibiotics to treat
Staphylococcus aureus is in dire need. Similarly, the genus
Bacillus can cause a wide range of issues, including infections,
anthrax, and endocarditis.4
Through the use of the safe test strains Staphylococcus
epidermidis and Bacillus subtilis, we can use a variety of
molecular and biochemical procedures to find and isolate new
antibiotic-producing bacteria. These strains, which are
evolutionarily similar to the ESKAPE strains, allow for the safe
testing and potential discovery of novel antibiotics against
Staphylococcus aureus and Bacillus anthracis. Identification
and isolation of antibiotic-producing bacteria will be reported
back into the global network of the Tiny Earth Project
Initiative.

DISCUSSION

Figure 2. Evidence of antibiotic producing isolates present
against both of my Gram-positive strains, Staphylococcus
epidermidis and Bacillus subtilis. Halos were present in the first
and third columns, Staphylococcus epidermidis and Bacillus
subtilis respectively. The middle column was a Gram-negative
bacteria, Erwinia carotovora. The plates were grown on LB at
28oC for 24 hours.

We were able to successful identify the genus of isolates CJ-1TSA and CJ-4-PDA as Pseudomonas and Bacillus. For these two
isolates we were able to conclude that they have the potential to
be broad spectrum antibiotics against both Staphylococcus
epidermidis and Bacillus subtilis.
Future directions of this project would include the isolation of the
actual secondary metabolite. This would involve organic and
biochemical separation techniques. Further directions would
include full genome sequencing through the Tiny Earth Project
Initiative and the potential identification of the structure of the
secondary metabolite.
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